Literature DB >> 20150361

Chromosome 9p and 10q losses predict unfavorable outcome in low-grade gliomas.

Caroline Houillier1, Karima Mokhtari, Catherine Carpentier, Emmanuelle Crinière, Yannick Marie, Audrey Rousseau, Gentian Kaloshi, Caroline Dehais, Julien Laffaire, Florence Laigle-Donadey, Khê Hoang-Xuan, Marc Sanson, Jean-Yves Delattre.   

Abstract

The loss of chromosomes 1p-19q is the only prognostic molecular alteration identified in low-grade gliomas (LGGs) to date. Search for loss of heterozygosity (LOH) on chromosomes 1p, 9p, 10q, and 19q was performed in a series of 231 LGGs. Loss of chromosomes 1p-19q was strongly correlated with prolonged progression-free survival (PFS) and overall survival (OS) in univariate and multivariate analyses. LOH on 9p and 10q were associated with shortened PFS (P = .01 and .03, respectively) on univariate analysis. On multivariate analysis, LOH on 9p remained significant for PFS (P = .05), whereas LOH on 10q had a significant effect on OS (P = .02). Search for LOH 9p and 10q appears to be a useful complement to analysis of chromosomes 1p-19q in LGGs.

Entities:  

Mesh：

Year:  2009        PMID： 20150361      PMCID： PMC2940555          DOI： 10.1093/neuonc/nop002

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


  22 in total

1.  Glioblastomas with an oligodendroglial component: a pathological and molecular study.

Authors:  J He; K Mokhtari; M Sanson; Y Marie; M Kujas; S Huguet; P Leuraud; L Capelle; J Y Delattre; J Poirier; K Hoang-Xuan
Journal:  J Neuropathol Exp Neurol       Date:  2001-09       Impact factor: 3.685

2.  Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study.

Authors:  E Shaw; R Arusell; B Scheithauer; J O'Fallon; B O'Neill; R Dinapoli; D Nelson; J Earle; C Jones; T Cascino; D Nichols; R Ivnik; R Hellman; W Curran; R Abrams
Journal:  J Clin Oncol       Date:  2002-05-01       Impact factor: 44.544

3.  Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas.

Authors:  S W Coons; P C Johnson; B W Scheithauer; A J Yates; D K Pearl
Journal:  Cancer       Date:  1997-04-01       Impact factor: 6.860

4.  Characterization of genomic alterations associated with glioma progression by comparative genomic hybridization.

Authors:  R G Weber; M Sabel; J Reifenberger; C Sommer; J Oberstrass; G Reifenberger; M Kiessling; T Cremer
Journal:  Oncogene       Date:  1996-09-05       Impact factor: 9.867

5.  A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844.

Authors:  A B Karim; B Maat; R Hatlevoll; J Menten; E H Rutten; D G Thomas; F Mascarenhas; J C Horiot; L M Parvinen; M van Reijn; J J Jager; M G Fabrini; A M van Alphen; H P Hamers; L Gaspar; E Noordman; M Pierart; M van Glabbeke
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-10-01       Impact factor: 7.038

6.  Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity.

Authors:  Brian Thiessen; John A Maguire; Kelly McNeil; David Huntsman; Montgomery A Martin; Doug Horsman
Journal:  J Neurooncol       Date:  2003-09       Impact factor: 4.130

7.  Treatment and survival of low-grade astrocytoma in adults--1977-1988.

Authors:  B M McCormack; D C Miller; G N Budzilovich; G J Voorhees; J Ransohoff
Journal:  Neurosurgery       Date:  1992-10       Impact factor: 4.654

Review 8.  Molecular pathways in the formation of gliomas.

Authors:  A von Deimling; D N Louis; O D Wiestler
Journal:  Glia       Date:  1995-11       Impact factor: 7.452

9.  Molecular-genetic characterisation of gliomas that recur as same grade or higher grade tumours.

Authors:  T J M Hulsebos; D Troost; S Leenstra
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

10.  Genomic changes in progression of low-grade gliomas.

Authors:  Ahmed Idbaih; Rosana Carvalho Silva; Emmanuelle Crinière; Yannick Marie; Catherine Carpentier; Blandine Boisselier; Sophie Taillibert; Audrey Rousseau; Karima Mokhtari; François Ducray; Joelle Thillet; Marc Sanson; Khê Hoang-Xuan; Jean-Yves Delattre
Journal:  J Neurooncol       Date:  2008-07-11       Impact factor: 4.130
View more
  11 in total

1.  Transcription factors NFIA and NFIB induce cellular differentiation in high-grade astrocytoma.

Authors:  Kok-Siong Chen; Caitlin R Bridges; Zorana Lynton; Jonathan W C Lim; Brett W Stringer; Revathi Rajagopal; Kum-Thong Wong; Dharmendra Ganesan; Hany Ariffin; Bryan W Day; Linda J Richards; Jens Bunt
Journal:  J Neurooncol       Date:  2019-11-23       Impact factor: 4.130

2.  Updates in prognostic markers for gliomas.

Authors:  Elisa Aquilanti; Julie Miller; Sandro Santagata; Daniel P Cahill; Priscilla K Brastianos
Journal:  Neuro Oncol       Date:  2018-11-09       Impact factor: 12.300

Review 3.  A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics.

Authors:  Martin J van den Bent; Michael Weller; Patrick Y Wen; Johan M Kros; Ken Aldape; Susan Chang
Journal:  Neuro Oncol       Date:  2017-05-01       Impact factor: 12.300

4.  Loss of heterozygosity 1p/19q and survival in glioma: a meta-analysis.

Authors:  Jiaxin Zhao; Wenjie Ma; Hong Zhao
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

Review 5.  Molecular Markers in Low-Grade Glioma-Toward Tumor Reclassification.

Authors:  Adriana Olar; Erik P Sulman
Journal:  Semin Radiat Oncol       Date:  2015-02-23       Impact factor: 5.934

6.  Loss of Heterozygosity of 9p Is Associated with Poorer Survival in Patients with Gliomas.

Authors:  Tingfen Huang; Shufa Li; Zhen Yang; Jicheng Liu; Yunwei Han
Journal:  Mol Neurobiol       Date:  2015-11-19       Impact factor: 5.590

7.  IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas.

Authors:  Ichiyo Shibahara; Yukihiko Sonoda; Masayuki Kanamori; Ryuta Saito; Yoji Yamashita; Toshihiro Kumabe; Mika Watanabe; Hiroyoshi Suzuki; Shunsuke Kato; Chikashi Ishioka; Teiji Tominaga
Journal:  Int J Clin Oncol       Date:  2011-10-06       Impact factor: 3.850

8.  Contribution of 1p, 19q, 9p and 10q Automated Analysis by FISH to the Diagnosis and Prognosis of Oligodendroglial Tumors According to WHO 2016 Guidelines.

Authors:  Karine Michaud; Marie de Tayrac; Myreille D'Astous; Céline Duval; Claudie Paquet; Oumar Samassekou; Peter Vincent Gould; Stéphan Saikali
Journal:  PLoS One       Date:  2016-12-28       Impact factor: 3.240

9.  Integrated systems-genetic analyses reveal a network target for delaying glioma progression.

Authors:  Liisi Laaniste; Prashant K Srivastava; Julianna Stylianou; Nelofer Syed; Silvia Cases-Cunillera; Kirill Shkura; Qingyu Zeng; Owen J L Rackham; Sarah R Langley; Andree Delahaye-Duriez; Kevin O'Neill; Matthew Williams; Albert Becker; Federico Roncaroli; Enrico Petretto; Michael R Johnson
Journal:  Ann Clin Transl Neurol       Date:  2019-08-17       Impact factor: 4.511

10.  Spatial and temporal evolution of distal 10q deletion, a prognostically unfavorable event in diffuse low-grade gliomas.

Authors:  Hinke F van Thuijl; Ilari Scheinin; Daoud Sie; Agusti Alentorn; Hendrik F van Essen; Martijn Cordes; Ruth Fleischeuer; Anja M Gijtenbeek; Guus Beute; Wimar A van den Brink; Gerrit A Meijer; Miek Havenith; Ahmed Idbaih; Khê Hoang-Xuan; Karima Mokhtari; Roel Gw Verhaak; Paul van der Valk; Mark A van de Wiel; Jan J Heimans; Eleonora Aronica; Jaap C Reijneveld; Pieter Wesseling; Bauke Ylstra
Journal:  Genome Biol       Date:  2014-09-23       Impact factor: 13.583
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.